ARCHIVED: NOT AVAILABLE FOR CREDIT
Practical Molecular Pathology: GI tract

 

This lecture will focus on three areas of practical molecular pathology for the gastrointestinal (GI) tract:

  1. PD-L1 testing in the gastrointestinal tract, with practical information on ordering criteria, interpretation and specimen submission for testing. This will focus on the recent FDA approval of PD-L1 testing for immunotherapy in gastroesophageal adenocarcinomas, as well as other indications for testing and treatment in other GI malignancies.
  2. Molecular pathology of gastrointestinal stromal tumors (GISTs), with emphasis on the spectrum of genetic alterations seen in GISTs, and their management implications.
  3. Her2 testing in gastroesophageal adenocarcinomas, with emphasis on the current CAP-ASCP-ASCO guidelines.

Originally presented on February 7, 2018, in Park City, Utah.

Lecture Presenter

Georgios Deftereos, MD, FCAP, FASCP

Georgios Deftereos, MD, FCAP, FASCP

Assistant Professor of Pathology
University of Utah School of Medicine
Medical Director, Molecular Oncology
ARUP Laboratories

Dr. Deftereos is an assistant professor of pathology at the University of Utah School of Medicine. He received his MD from the University of Bari Aldo Moro in Italy. Prior to his pathology training, Dr. Deftereos completed a research fellowship focusing on HPV and gynecological malignancies at the University of Washington in Seattle, Washington. He then completed a residency in anatomic and clinical pathology at Allegheny General Hospital in Pittsburgh, Pennsylvania, followed by consecutive clinical fellowships in cytopathology and molecular genetic pathology at the University of Washington. Dr. Deftereos provides service in the areas of molecular oncology and cytopathology. His research interests include epigenetics of solid tumors and minimally invasive precision diagnostics, with emphasis on the use of molecular testing in cytopathology of solid tumors.

Objectives

After this presentation, participants will be able to:

  • Describe clinical indications for immunotherapy and PD-L1 testing in GI tract malignancies
  • Identify criteria for specimen submission and interpretation of PD-L1 staining in gastroesophageal adenocarcinomas
  • Describe the most common mutations seen in GISTs, and their implications in management
  • Recognize current guidelines regarding Her2 testing in gastroesophageal adenocarcinomas

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories